project id: TCGA-CESC; case submitter id: TCGA-C5-A2M2; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.88; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.5; rna integrity number: 8.6; age at index: 56; days to birth: -20480; days to death: 1011; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Dead; year of birth: 1953; age at diagnosis: 20480; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 25.0; figo stage: Stage IB2; icd 10 code: C53.9; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Cervix uteri; synchronous malignancy: No; tissue or organ of origin: Cervix uteri; tumor grade: Not Reported; year of diagnosis: 2009; treatment or therapy: not reported; alcohol history: Not Reported; cigarettes per day: 0.4383561643835616; pack years smoked: 8.0; is ffpe: false; composition: Not Reported; days to collection: 774; days to sample procurement: 0; initial weight: 140.0; portion submitter id: TCGA-C5-A2M2-01A-21; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 100.0; percent tumor nuclei: 75.0;